Zentalis Pharmaceuticals Announces $80.5M Common Stock Offering

What happened

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing cancer therapies, announced an underwritten public offering of 23,000,000 shares of its common stock. The offering was priced at $3.50 per share, with total gross proceeds of approximately $80.5 million before underwriting discounts and expenses.

The company granted underwriters a 30-day option to purchase up to an additional 3,450,000 shares at the same price, which would add roughly $12.1 million if fully exercised. Shares were expected to be delivered on or about August 17, 2026.

The stock fell 14.22% on the event date to close at $3.56, down from $4.15 the prior day, on volume about four times its average, a typical reaction to the dilutive effect of a new share sale.

The filing

The offering was made under a Form 424B5 prospectus supplement filed with the SEC on August 14, 2026, pursuant to Rule 424(b)(5). This document supplements a base prospectus dated April 4, 2025, and details the specific terms of this offering.

Zentalis said it plans to use the net proceeds to fund clinical development and manufacturing of its lead drug candidate azenosertib, a WEE1 inhibitor being studied for platinum-resistant ovarian cancer, and for working capital and general corporate purposes.

The underwriters for the offering are TD Cowen, Guggenheim Securities, Oppenheimer & Co., H.C. Wainwright & Co., and Rodman & Renshaw LLC.

What this means

A shelf takedown is a type of public offering where a company sells shares from a pre-registered shelf registration statement, allowing faster access to capital. Here, Zentalis is selling new shares to raise cash, which increases the total share count and dilutes existing shareholders, often causing the stock price to fall.

A 424B5 is the SEC form used to file a prospectus supplement for a shelf offering. It provides the specific terms of the offering—such as the number of shares and price—while the base prospectus contains general company and security information.

Zentalis is a clinical-stage biopharmaceutical company — it has no approved products and no current revenue. It reported zero revenue for the year ended December 31, 2025, meaning it relies on funding from offerings like this to support its clinical trials.

The company's lead candidate, azenosertib, is an experimental oral drug that inhibits the WEE1 enzyme, a protein involved in DNA damage repair in cancer cells. Zentalis is currently running a Phase 2 trial, DENALI, and a Phase 3 confirmatory trial, ASPENOVA, in patients with a specific type of ovarian cancer.

After the offering, the company will have about 94.7 million shares outstanding, or about 98.1 million if the underwriters' option is fully exercised. The company will use the proceeds to advance its drug development programs, which are at a stage where clinical trial results are expected in the first half of 2027.